Literature DB >> 25395949

Compliance with severe sepsis bundles and its effect on patient outcomes of severe community-acquired pneumonia in a limited resources country.

Qi Guo1, Hai-Yan Li2, Yi-Min Li3, Ling-Bo Nong3, Yuan-Da Xu3, Guo-Qing He3, Xiao-Qing Liu3, Mei Jiang3, Zheng-Iun Xiao3, Nan-Shan Zhong3.   

Abstract

INTRODUCTION: Validation of compliance with severe sepsis bundles is still needed. The purpose of this study was to determine compliance and its outcomes in severe community-acquired pneumonia (CAP) patients in a limited resources country.
MATERIAL AND METHODS: A prospective cohort study of 212 severe CAP patients was carried out. The implementation programme was organized into two continuous phases. The primary outcomes were compliance and hospital mortality.
RESULTS: Compliance with administration of antibiotics and vasopressors as well as plateau pressure on average < 30 cm H2O was high in both groups. In the bundles group, patients received more serum lactate monitoring (62.3% vs. 11.3%), more blood cultures (47.1% vs. 24.5%), more fluid resuscitation (63.2% vs. 26.4%) and volumes infused (1319.8 ±1107.4 ml vs. 461.9 ±799.3 ml), more inotropic dobutamine and/or packed red blood cells (21.7% vs. 10.0%), more low-dose steroids (56.5% vs. 15.0%), and more glucose control (51.9% vs. 6.6%) compared with such patients in the control group. The rates of total compliance with 6-hour, 24-hour, and 6/24-hour bundles in the prospective period were 47.1%, 51.9%, and 42.5%, respectively. Hospital mortality was reduced from 44.3% to 29.2% (p = 0.023) in the bundles group, and the compliant subgroup had a more than twofold decrease in mortality (17.8% vs. 37.7%, p = 0.003). Serum lactate measured, blood cultures, and fluid resuscitation showed independent relationships with decreased mortality.
CONCLUSIONS: Total compliance was relatively low, but the implementation of severe sepsis bundles could clearly reduce mortality from severe CAP.

Entities:  

Keywords:  compliance; mortality; septic shock; severe community-acquired pneumonia; severe sepsis; severe sepsis bundles

Year:  2014        PMID: 25395949      PMCID: PMC4223141          DOI: 10.5114/aoms.2014.46216

Source DB:  PubMed          Journal:  Arch Med Sci        ISSN: 1734-1922            Impact factor:   3.318


Introduction

The mortality rate due to pneumonia has shown little improvement over time despite advances in antimicrobial therapy and improved intensive care medicine [1-3]. It was as high as 58% when patients with severe community-acquired pneumonia (CAP) were admitted to the intensive care unit (ICU) [4]. The Surviving Sepsis Campaign (SSC) was launched in 2002 as a collaborative initiative of three international organizations. The initial guidelines were published in 2004 and an updated version in 2008. Its objective was, through the development and promulgation of evidence-based guidelines that facilitated the application of knowledge derived from clinical trials to bedside practice, to effect a 25% reduction in the relative risk of death from severe sepsis and septic shock [5, 6]. The development and publication of guidelines often do not lead to changes in clinical behaviour and guidelines are rarely, if ever, integrated into bedside practice in a timely fashion. The SSC undertook a broad educational programme to implement them by integrating their recommendations into resuscitation and management bundles. The feasibility of implementing severe sepsis bundles was validated in the United States, Europe and South America and as a result the mortality from severe sepsis was reduced [7-19]. Compliance with the bundles and its impact were heterogeneous among institutions and countries [20]. Therefore, the primary evidence obtained so far lacks enough substance and quality to promote the guidelines as a global standard of care for universal applicability. Further evaluations and primary studies are still needed [21], especially in countries with limited resources. There has only been one report so far in English of compliance with the bundles in Asia [22]. The study did not aim to evaluate the impact of the sepsis protocol during a one-month observation period. As the centres included in this study might not be fully representative, achievement rates reported might overestimate or underestimate the true degree of compliance with recommended care and should be interpreted with caution. On the other hand, the healthcare systems in many Asian countries differ greatly from those in the above-mentioned developed countries. Therefore, further studies are still warranted in Asia. Pneumonia is the major source of infection in severe sepsis patients in our respiratory ICU (RICU). Therefore, we decided to study this population. Adult patients who suffered from severe CAP with severe sepsis or septic shock were enrolled in this study to determine compliance with severe sepsis bundles and to report its effect on patient outcomes in a limited resources country.

Material and methods

Design and setting

A prospective observational cohort study from 1 November 2006 to 31 July 2008 was carried out on adult patients who met criteria for severe CAP with severe sepsis or septic shock presenting to the RICU in a Chinese affiliated tertiary hospital of a medical college. Similar patients presenting between 1 November 2004 and 31 October 2006 were used as historical controls.

Criteria for enrolment

The CAP was defined as an acute infection of the pulmonary parenchyma associated with an acute infiltrate on the chest radiograph with two or more symptoms including fever (> 38°C), hypothermia (< 36°C), rigors, sweats, new cough or change in colour of respiratory secretions, chest discomfort or dyspnoea. Severe CAP with severe sepsis or septic shock was defined when one of two major criteria (the need for invasive mechanical ventilation or vasopressors) was fulfilled. Septic shock was defined as systolic arterial pressure (SAP) < 90 mm Hg, mean arterial pressure (MAP) < 60 mm Hg, or a reduction in SAP of > 40 mm Hg from baseline, which was persistent, despite adequate fluid resuscitation, in the absence of other causes for hypotension [3, 23, 24]. Exclusion criteria were patients who: a) had a cardiac arrest, or b) had end-stage chronic disease (malignancy, chronic renal failure, chronic obstructive pulmonary disease, or acquired immune deficiency syndrome). Patients with severe heart failure, with neoplastic disease (but not in the end stage), with severe asthma, with chronic renal failure stage I, or with brain stroke were also enrolled.

Components of severe sepsis bundles

Six-hour and 24-hour severe sepsis bundles adapted from the SSC standard sepsis resuscitation and management bundles are listed in Table I [25]. Since the use of recombinant human activated protein C is not approved in China, it was eliminated from the 24-hour severe sepsis bundle.
Table I

Severe sepsis bundles

6-hour severe sepsis bundle:

Serum lactate measured.

Blood cultures obtained prior to antibiotic administration.

Initial empirical antibiotics administered within 1 h.

In the event of hypotension and/or serum lactate > 4 mmol/l:

Deliver an initial minimum of 20 ml/kg of crystalloid (or colloid equivalent: 1.1 ml/kg of 20% albumin or 4.8 ml/kg of 6% hydroxyethyl starch).

Apply vasopressors (noradrenaline or dopamine) for hypotension not responding to initial fluid resuscitation to maintain mean arterial pressure (MAP) ≥ 65 mm Hg.

In the event of persistent septic shock and/or serum lactate > 4 mmol/l, administration of inotropic dobutamine and/or transfusion of packed red blood cells (when haemoglobin (Hb) < 70 g/l) to achieve a central venous pressure (CVP) of ≥ 8 mm Hg and central venous oxygen saturation (ScvO2) of ≥ 70%.

24-hour severe sepsis bundle:

Low dosage corticosteroid (40–60 mg/day of methylprednisolone) administered for septic shock requiring continued infusion of vasopressors.

Glucose control maintained < 8.3 mmol/l.

For mechanically ventilated patients maintain inspiratory plateau pressures < 30 cm H2O.

Severe sepsis bundles Serum lactate measured. Blood cultures obtained prior to antibiotic administration. Initial empirical antibiotics administered within 1 h. In the event of hypotension and/or serum lactate > 4 mmol/l: Deliver an initial minimum of 20 ml/kg of crystalloid (or colloid equivalent: 1.1 ml/kg of 20% albumin or 4.8 ml/kg of 6% hydroxyethyl starch). Apply vasopressors (noradrenaline or dopamine) for hypotension not responding to initial fluid resuscitation to maintain mean arterial pressure (MAP) ≥ 65 mm Hg. In the event of persistent septic shock and/or serum lactate > 4 mmol/l, administration of inotropic dobutamine and/or transfusion of packed red blood cells (when haemoglobin (Hb) < 70 g/l) to achieve a central venous pressure (CVP) of ≥ 8 mm Hg and central venous oxygen saturation (ScvO2) of ≥ 70%. Low dosage corticosteroid (40–60 mg/day of methylprednisolone) administered for septic shock requiring continued infusion of vasopressors. Glucose control maintained < 8.3 mmol/l. For mechanically ventilated patients maintain inspiratory plateau pressures < 30 cm H2O.

Implementation of severe sepsis bundles

The 21-month implementation programme was organized into two continuous phases that incorporated education and intervention. During the education phase (in November 2006), conference lectures were delivered to all physicians and nurses in the RICU and the emergence department (ED) on the SSC, severe CAP definitions and recognition, haemodynamic monitoring, and the initiation and components of the bundles. Timely initiation and completion of the bundles were emphasized. Time zero was defined as the point when the diagnosis of severe CAP was established in the ED. Serum lactate measured, blood cultures obtained prior to antibiotic administration, and initial empirical antibiotics administered within 1 h were considered once severe CAP was diagnosed, and the admission was fulfilled through an Emergency Path. Insulin was intravenously administered by infusion pump to maintain blood glucose level < 8.3 mmol/l. In the intervention phase (between 1 December 2006 and 31 July 2008), the personnel were issued with a personal pocket information card as a daily reminder of the processes involved in the delivery of the bundles and weekly feedback was provided by the senior physicians to all personnel in order to optimize compliance. The feedback incorporated oral information, cards posted in the RICU and the ED, and group discussions.

Definition of total compliance

On the basis of severity of illness, implementation of all necessary components of 6-hour, 24-hour, or 6/24-hour severe sepsis bundles was defined as total compliance. Had some components been unnecessary on the basis of the SSC, a patient would still have been regarded as receiving all components as long as the remaining ones were implemented.

Approval of study design

The study was approved by our Institutional Review Boards (Review Board of Guangdong Medical College and Review Board of Guangzhou Medical University). Ethical approval from the regulation committee (Ethical Committee of Guangzhou) was granted for the study protocol with a waiver of informed consent.

Outcomes

The primary outcomes were compliance and hospital mortality. Secondary outcomes incorporated ventilator-free days estimated from the ICU length of stay and parameters at 72 h after start of therapy. The endpoints for evaluation were referred to Kortgen's study [9]. Laboratory variables were measured by the hospital clinical laboratory.

Grouping and data collection

One hundred and thirteen patients were enrolled in the cohort study period. Seven cases were excluded from this study according to the exclusion criteria. The remaining 106 patients, 46 (43.4%) patients who suffered from septic, shock were enrolled in the bundles group, which was further divided into the compliant and the non-compliant subgroups at the end of the study according to total compliance with 6/24-hour severe sepsis bundles. One hundred and six discharged patients who were selected through the formal case-control method to match all baseline characteristics of the patients in the prospective group were assigned to the control group. A senior physician was in charge of collecting the data. Demographics, co-morbid conditions, vital signs, laboratory data, and compliance data were collected. The volumes of 6% hydroxyethyl starch and 20% albumin were converted into equivalent dosages of crystalloid [26]. Severity-of-illness scores were calculated, including the acute physiology and chronic health evaluation (APACHE) II scores and sequential organ failure assessment (SOFA) scores. Missing values were assumed to be normal [27]. Indeed, patients with less severe illness were more likely to have missing values for laboratory findings. The statistician was blinded to the study and study hypothesis.

Statistical analysis

All statistical analyses were performed with Statistical Package for the Social Science for Windows version 13.0 (SPSS, Chicago, IL, USA). Categorical variables and continuous data were reported as percentages and mean ± standard deviation (SD), respectively. Chi-square (χ2) test and independent-samples t test were used when appropriate in testing for differences between groups. Univariate and multivariate logistic regression analyses were employed. All components of severe sepsis bundles were entered into a multivariate logistic regression model. Statistical significance was defined as p < 0.05.

Results

Baseline characteristics of patients

No significant differences were observed between the two patient groups with respect to baseline characteristics (Table II). The aetiologies were not detected in many patients in the control group. Hence, the data were not shown. The initial antibiotic regimens in the two groups were consistent with the guidelines on the management of CAP [3, 28], in addition to subsequently cultured pathogens. All patients in the bundles group had central venous pressure (CVP) and central venous oxygen saturation (ScvO2) measured and the averages were 9.4 ±1.7 mm Hg and 68.3 ±9.8%, respectively. However, these parameters were not measured in most patients in the control group. Therefore, the comparison could not be drawn.
Table II

Baseline characteristics of patients (mean ± SD, n = 212)

VariableControl groupBundles groupValue of χ2 or t Value of p
Age [years]62.8 ±14.264.0 ±15.20.9410.348
Male sex (%)77.466.13.3470.067
Body temperature [°C]37.6 ±1.037.8 ±1.31.4850.149
Heart rate [beats/min]113.6 ±22.4116.4 ±27.60.8270.409
Respiratory rate [breaths/min]29.0 ±6.729.9 ±10.00.7800.436
MAP [mm Hg]81.1 ±18.281.0 ±19.90.0350.972
Blood glucose [mmol/l]9.0 ±2.69.1 ±3.30.2480.804
White blood cell count [109/l]13.6 ±7.515.0 ±6.61.5320.127
PaO2/FIO2 [mm Hg]141.5 ±42.9150.2 ±58.41.2360.218
Serum creatinine [µmol/l]106.4 ±53.9111.7 ±79.60.5680.571
Total bilirubin [µmol/l]25.3 ±38.929.0 ±69.90.4690.639
Alanine aminotransferase [U/l]88.0 ±155.558.7 ±115.01.5590.121
Platelets [109/l]211.7 ±108.7205.1 ±94.40.4700.639
Haematocrit (%)33.6 ±6.432.9 ±6.50.8150.416
Serum lactate [mmol/l]2.8 ±1.43.1 ±1.50.7480.465
APACHE II score15.4 ±5.315.9 ±7.50.9910.317
SOFA score6.1 ±3.46.9 ±4.71.4640.145
Shock (%)37.743.40.7040.401
Comorbidities (%):
 Hypertension38.440.60.2650.529
 Coronary heart disease11.36.61.4450.229
 Heart failure12.310.40.1880.665
 Chronic obstructive pulmonary disease26.433.01.1070.293
 Diabetes mellitus14.218.90.8560.355
 Liver disease7.59.40.2430.622
 Tumour19.811.32.9070.088
 Nervous system disease7.59.40.2430.622
 Chronic renal insufficiency7.55.70.3060.580
Alcohol abuse (%)5.71.92.0780.149
Smoking (%)34.935.80.0210.886
Duration to establish severe CAP diagnosis [min]61.8 ±57.260.3 ±49.50.2530.712
Antibiotic therapy:
 Antibiotics adequate (%)93.795.80.3190.527
 Duration [days]12.6 ±14.312.9 ±15.10.2370.872

PaO2/FIO2 – arterial oxygen pressure/fraction inspired oxygen.

Baseline characteristics of patients (mean ± SD, n = 212) PaO2/FIO2 – arterial oxygen pressure/fraction inspired oxygen.

Compliance with severe sepsis bundles

Compliance with administration of antibiotics within 1 h, administration of vasopressors (if necessary), and plateau pressure on average < 30 cm H2O was high in both groups (p, 0.206, 0.085, 0.149, respectively; Figure 1). Significant differences were found between the two groups with respect to serum lactate measured, blood cultures obtained prior to antibiotic administration, initiation of fluid resuscitation and volumes infused, administration of inotropic dobutamine and/or transfusion of packed red blood cells, low-dose steroids (if necessary), and glucose control (p, < 0.001, 0.001, < 0.001, 0.005, < 0.001, and < 0.001, respectively; Figure 1). Inotropic dobutamine was administered to 17 patients, 11 patients simultaneously received an average 4-unit transfusion of packed red cells in the bundles group, whereas the numbers in the control group were 4, 2, and 2, respectively. The average volume infused within 6 h in the bundles group was more than that in the control group (1319.8 ±1107.4 ml vs. 461.9 ±799.3 ml; p < 0.001). The rates of total compliance with 6-hour, 24-hour, and 6/24-hour bundles in the bundles group were 47.1%, 51.9%, and 42.5%, whereas the rates in the control group were 0.0%, 0.0%, and 0.0% (p, < 0.001, < 0.001, and < 0.001), respectively.
Figure 1

Compliance with components of severe sepsis bundles (n = 212)

RBC – red blood cells

Compliance with components of severe sepsis bundles (n = 212) RBC – red blood cells

Outcomes at 72 hours

Significant differences were observed between the two groups in respiratory rate, MAP, blood glucose, arterial oxygen pressure/fraction inspired oxygen (PaO2/FIO2), serum creatinine, serum lactate, APACHE II scores, and SOFA scores at 72 h after the start of therapy (Table III). Central venous pressure increased significantly from 9.4 ±1.7 mm Hg at baseline to 10.9 ±1.8 mm Hg at 72 h after the start of therapy in the bundles group (p < 0.001), as did ScvO2 during this time period (68.3 ±9.8% vs. 79.5 ±3.8%, p < 0.001).
Table III

Outcomes at 72 h (mean ± SD, n = 212)

ParameterControl groupBundles groupValue of t Value of p
Body temperature [°C]37.2 ±1.037.3 ±0.90.2360.814
Heart rate [beats/min]100.3 ±21.599.7 ±17.50.2140.831
Respiratory rate [breaths/min]27.7 ±7.025.2 ±7.62.5420.012
MAP [mm Hg]87.8 ±12.991.4 ±10.62.1850.030
Blood glucose [mmol/l]8.9 ±2.37.4 ±1.85.360< 0.001
White blood cell count [109/l]13.0 ±8.914.2 ±7.51.0340.302
PaO2/FIO2 [mm Hg]172.4 ±101.6223.1 ±83.33.971< 0.001
Serum creatinine [µmol/l]118.3 ±87.597.0 ±52.62.1450.033
Total bilirubin [µmol/l]33.7 ±64.935.7 ±98.90.1790.858
Alanine aminotransferase [U/l]254.8 ±1219.251.2 ±50.91.7180.087
Platelets [109/l]159.6 ±109.8162.0 ±112.30.1610.872
Haematocrit (%)30.7 ±5.429.8 ±5.31.2290.221
Serum lactate [mmol/l]4.1 ±3.92.5 ±0.72.9790.004
APACHE II score11.3 ±5.79.5 ±4.72.6370.009
SOFA score6.6 ±4.15.4 ±4.32.1700.031
Outcomes at 72 h (mean ± SD, n = 212)

Hospital mortality and ventilator-free days

Hospital mortality in patients enrolled in the bundles group compared with that in the control group was 29.2% vs. 44.3% (χ2 = 5.192, p = 0.023), reflecting a 15.1% absolute reduction in mortality. There was a significantly decreased odds ratio (OR) for mortality in patients who received bundles treatment (OR = 0.393; 95% confidence interval (CI), 0.209–0.741; p = 0.004). A multivariate logistic regression analysis was performed. Serum lactate measured, blood cultures obtained prior to antibiotic administration, and fluid resuscitation showed independent relationships with decreased mortality (OR = 0.112, 0.459, and 0.247; 95% CI: 0.037–0.334, 0.211–0.997, and 0.091–0.635; p, < 0.001, 0.039, and < 0.001; respectively). The two subgroups were comparable with respect to age, gender, and severity at baseline (Table IV). Compared with the non-compliant subgroup, the compliant subgroup had a more than twofold decrease in mortality (17.8% vs. 37.7%. OR = 0.222; 95% CI: 0.082–0.602; p = 0.003).
Table IV

Baseline characteristics of patients and mortality in the bundles group according to total compliance (mean ± SD, n = 106)

ParameterCompliant subgroup (n = 45)Non-compliant subgroup (n = 61)Value of χ2 or t Value of p
Age [years]61.7 ±19.261.4 ±15.50.0960.924
Male sex (%)68.963.90.2830.594
MAP [mm Hg]81.6 ±21.080.5 ±19.20.2890.773
White blood cell count [109/l]16.5 ±7.414.0 ±5.71.9260.048
PaO2/FIO2 [mm Hg]145.3 ±63.2162.1 ±52.21.4600.148
APACHE II score16.9 ±7.315.2 ±7.61.2060.231
SOFA score7.4 ±5.36.0 ±4.01.4700.146
Shock (%)44.431.11.9690.161
Mortality, n (%)8 (17.8)23 (37.7)4.9700.026
Baseline characteristics of patients and mortality in the bundles group according to total compliance (mean ± SD, n = 106) All patients in both groups were mechanically ventilated. In the bundles group, patients had significant longer ventilator-free days compared with such patients in the control group (6.1 ±6.7 vs. 3.9 ± 6.6 days; p = 0.017).

Discussion

Compliance with administration of antibiotics and vasopressors and plateau pressure on average < 30 cm H2O was high. The rates of total compliance with the bundles in the prospective period increased significantly. Hospital mortalities were significantly reduced in the bundles group and in the compliant subgroup. Serum lactate measurement, blood cultures, and fluid resuscitation were independently associated with decreased mortality. Initial empirical antibiotics were generally administered within 1 h, suggesting that our physicians know and readily accept the concept of the association between timing of antibiotic administration and outcomes [29-31]. Nguyen et al. [32] found that physicians were more willing to accept hypotension than serum lactate concentration as a criterion to initiate resuscitation, as in the current study; that is to say, some patients with serum lactate > 4 mmol/l might not receive fluid resuscitation. Therefore, compliance with initiation of fluid resuscitation was not high. Compliance with administration of vasopressors was high in both groups, but the implementation of administration of inotropic dobutamine and/or transfusion of packed red blood cells was poor (the worst), suggesting that our physicians did not put more emphasis on the imbalance between oxygen consumption and supply when dealing with persistent septic shock. Glucose control was the lowest compliant element of the 24-hour bundle in our study despite continuous insulin infusion. Scrupulous avoidance of iatrogenic hypoglycaemia frequently resulted in blood glucose > 8.3 mmol/l. Our physicians found that weekly feedback facilitated the implementation of the bundles. Levy et al. [13] also reported that compliance with the entire resuscitation bundle and with the entire management bundle increased to 31.3% and 36.1%, respectively, by the end of 2 years. The compliance rate with all elements of the sepsis resuscitation bundle increased from 12.7% at baseline to 37.7% and 53.7% during the weekly feedback and sepsis response team activation periods, respectively (p < 0.001) [33]. Compliance with a 6-hour severe sepsis bundle at the beginning was low and increased by the end (from 8.1% to 53.7%) [8]. The total compliance was not high in the current study, as was it in Phua's study (compliance rates for the resuscitation and management bundles were 7.6% and 3.5%, respectively) [22] and Schramm's study (the compliance rate with all elements of the sepsis resuscitation bundle increased from 12.7% at baseline to 37.7% and 53.7% during the weekly feedback and sepsis response team activation periods, respectively) [33]. Two of the major factors limiting high total compliance in our study might be lack of sufficient staff in the RICU and the ED and difficulty in maintaining the time intervals. This is likely to be improved by better staff awareness of the benefits and timeliness of implementing the bundles. Levy's report emphasized the importance of early management and was reminiscent of the concept of the golden 6 h and silver 24 h for trauma [34]. The SSC has had some impact; however, there is still a long way to go [35]. What about the feasibility of implementing the bundles in undeveloped countries? Our institution is the state key laboratory of respiratory diseases. This might be envisaged to interpret the higher compliance in the current study, compared with that in Phua's multicentre study [22]. It is likely to imply that the implementation of the bundles might be very arduous in many undeveloped countries, especially those in Asia. This might be an important message that would have potential to improve care on a global basis. Hence, future long-term multicentre studies should be performed to assess the compliance in limited resources countries. The patients without hypotension would still have received fluid resuscitation had serum lactate been measured, which could be of survival benefit. Similarly, obtaining blood cultures may be useful if the blood cultures revealed a pathogen that was not being treated effectively with the antibiotics chosen. If the clinician was then able to act upon that information and correct the antibiotic choice, this could have an impact on mortality. These considerations might explain why serum lactate measured and blood cultures showed independent relationships with decreased mortality. Our current data revealed the pivotal role of implementing severe sepsis bundles in the management of severe CAP. The 15.1% absolute hospital mortality reduction in our study was similar to that reported by Nguyen et al. (18.7%) [8], Kortgen et al. (26%) [9], Micek et al. (18.3%) [11], Lefrant et al. (13.0%) [16], Schramm et al. (8.3%) [33], and Castellanos-Ortega et al. (19.8%) [36]. In the compliant subgroup, patients had a more than twofold decrease in mortality compared with such patients in the non-compliant subgroup in the current study. Gao et al. [7] reported that the mortality in the compliant group decreased from 49% to 23% (p = 0.01), compared with the non-compliant group. Mortality was 61.1% in the non-bundle group versus 20% with the bundle (p < 0.001) [15]. Delivery of the interventions had an association with reduced mortality: for the sepsis six, 20.0% compared with 44.1% (p < 0.001); for the resuscitation bundle, 5.9% compared with 51% (p < 0.001) [14]. Several limitations of this study deserve comment. Comparing crude mortality rates before and after an intervention ignores the underlying trend of decreased mortality and might give rise to misleading conclusions. Another limitation is that it was performed only in patients with severe CAP and not other types of sepsis from other sources of infection such as intra-abdominal infections or soft tissue infections. There might be some imbalance in the aetiology of pneumonia between the two groups. The study was not multicentre. Finally, long-term follow-up was not done; therefore, it was uncertain whether the implementation of the bundles and its effect would be similar to what Ferrer et al. [37] reported (during long-term follow-up, compliance with the sepsis resuscitation bundle returned to baseline but compliance with the sepsis management bundle and mortality remained stable with respect to the post-intervention period). In conclusion, total compliance was relatively low, but the implementation of severe sepsis bundles was associated with a significant decrease in mortality from severe CAP.
  36 in total

1.  Before-after study of a standardized hospital order set for the management of septic shock.

Authors:  Scott T Micek; Nareg Roubinian; Tim Heuring; Meghan Bode; Jennifer Williams; Courtney Harrison; Theresa Murphy; Donna Prentice; Brent E Ruoff; Marin H Kollef
Journal:  Crit Care Med       Date:  2006-11       Impact factor: 7.598

2.  The sepsis six and the severe sepsis resuscitation bundle: a prospective observational cohort study.

Authors:  Ron Daniels; Tim Nutbeam; Georgina McNamara; Clare Galvin
Journal:  Emerg Med J       Date:  2010-10-29       Impact factor: 2.740

3.  Prospective external validation of the clinical effectiveness of an emergency department-based early goal-directed therapy protocol for severe sepsis and septic shock.

Authors:  Alan E Jones; Anne Focht; James M Horton; Jeffrey A Kline
Journal:  Chest       Date:  2007-06-15       Impact factor: 9.410

Review 4.  Improving mortality in sepsis: analysis of clinical trials.

Authors:  Flavia R Machado; Bruno F Mazza
Journal:  Shock       Date:  2010-09       Impact factor: 3.454

5.  Early changes in organ function predict eventual survival in severe sepsis.

Authors:  Mitchell M Levy; William L Macias; Jean-Louis Vincent; James A Russell; Eliezer Silva; Benjamin Trzaskoma; Mark D Williams
Journal:  Crit Care Med       Date:  2005-10       Impact factor: 7.598

6.  Implementation of a bundle of quality indicators for the early management of severe sepsis and septic shock is associated with decreased mortality.

Authors:  H Bryant Nguyen; Stephen W Corbett; Robert Steele; Jim Banta; Robin T Clark; Sean R Hayes; Jeremy Edwards; Thomas W Cho; William A Wittlake
Journal:  Crit Care Med       Date:  2007-04       Impact factor: 7.598

7.  Impact of the Surviving Sepsis Campaign on the recognition and management of severe sepsis in the emergency department: are we failing?

Authors:  Helen Lindsay Cronshaw; Ron Daniels; Anthony Bleetman; Emma Joynes; Mark Sheils
Journal:  Emerg Med J       Date:  2010-07-26       Impact factor: 2.740

8.  Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008.

Authors:  R Phillip Dellinger; Mitchell M Levy; Jean M Carlet; Julian Bion; Margaret M Parker; Roman Jaeschke; Konrad Reinhart; Derek C Angus; Christian Brun-Buisson; Richard Beale; Thierry Calandra; Jean-Francois Dhainaut; Herwig Gerlach; Maurene Harvey; John J Marini; John Marshall; Marco Ranieri; Graham Ramsay; Jonathan Sevransky; B Taylor Thompson; Sean Townsend; Jeffrey S Vender; Janice L Zimmerman; Jean-Louis Vincent
Journal:  Crit Care Med       Date:  2008-01       Impact factor: 7.598

9.  Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department.

Authors:  David F Gaieski; Mark E Mikkelsen; Roger A Band; Jesse M Pines; Richard Massone; Frances F Furia; Frances S Shofer; Munish Goyal
Journal:  Crit Care Med       Date:  2010-04       Impact factor: 7.598

10.  The impact of compliance with 6-hour and 24-hour sepsis bundles on hospital mortality in patients with severe sepsis: a prospective observational study.

Authors:  Fang Gao; Teresa Melody; Darren F Daniels; Simon Giles; Samantha Fox
Journal:  Crit Care       Date:  2005-11-11       Impact factor: 9.097

View more
  10 in total

Review 1.  Early management of sepsis with emphasis on early goal directed therapy: AME evidence series 002.

Authors:  Zhongheng Zhang; Yucai Hong; Nathan J Smischney; Han-Pin Kuo; Panagiotis Tsirigotis; Jordi Rello; Win Sen Kuan; Christian Jung; Chiara Robba; Fabio Silvio Taccone; Marc Leone; Herbert Spapen; David Grimaldi; Sven Van Poucke; Steven Q Simpson; Patrick M Honore; Stefan Hofer; Pietro Caironi
Journal:  J Thorac Dis       Date:  2017-02       Impact factor: 2.895

2.  Care bundles for improving outcomes in patients with COVID-19 or related conditions in intensive care - a rapid scoping review.

Authors:  Valerie Smith; Declan Devane; Alistair Nichol; David Roche
Journal:  Cochrane Database Syst Rev       Date:  2020-12-21

3.  Recommendations for infection management in patients with sepsis and septic shock in resource-limited settings.

Authors:  C Louise Thwaites; Ganbold Lundeg; Arjen M Dondorp
Journal:  Intensive Care Med       Date:  2016-06-21       Impact factor: 17.440

4.  Implementation of sepsis bundles in public hospitals in Brazil: a prospective study with heterogeneous results.

Authors:  Flavia Ribeiro Machado; Elaine Maria Ferreira; Pierre Schippers; Ilusca Cardoso de Paula; Letícia Sandre Vendrame Saes; Francisco Ivanildo de Oliveira; Paula Tuma; Wilson Nogueira Filho; Felipe Piza; Sandra Guare; Cláudia Mangini; Gustavo Ziggiatti Guth; Luciano Cesar Pontes Azevedo; Flavio Geraldo Resende Freitas; Jose Luiz Gomes do Amaral; Nacime Salomão Mansur; Reinaldo Salomão
Journal:  Crit Care       Date:  2017-10-31       Impact factor: 9.097

5.  Cold-inducible RNA-binding protein might determine the severity and the presences of major/minor criteria for severe community-acquired pneumonia and best predicted mortality.

Authors:  Qi Guo; Wei-Dong Song; Hai-Yan Li; Ming Li; Xiao-Ke Chen; Hui Liu; Hong-Lin Peng; Hai-Qiong Yu; Nian Liu; Zhong-Dong Lü; Li-Hua Liang; Qing-Zhou Zhao; Mei Jiang
Journal:  Respir Res       Date:  2020-07-20

Review 6.  Early goal-directed therapy in severe sepsis and septic shock: insights and comparisons to ProCESS, ProMISe, and ARISE.

Authors:  H Bryant Nguyen; Anja Kathrin Jaehne; Namita Jayaprakash; Matthew W Semler; Sara Hegab; Angel Coz Yataco; Geneva Tatem; Dhafer Salem; Steven Moore; Kamran Boka; Jasreen Kaur Gill; Jayna Gardner-Gray; Jacqueline Pflaum; Juan Pablo Domecq; Gina Hurst; Justin B Belsky; Raymond Fowkes; Ronald B Elkin; Steven Q Simpson; Jay L Falk; Daniel J Singer; Emanuel P Rivers
Journal:  Crit Care       Date:  2016-07-01       Impact factor: 9.097

Review 7.  Severe community-acquired pneumonia: timely management measures in the first 24 hours.

Authors:  Jason Phua; Nathan C Dean; Qi Guo; Win Sen Kuan; Hui Fang Lim; Tow Keang Lim
Journal:  Crit Care       Date:  2016-08-28       Impact factor: 9.097

8.  Mortality of adult intensive care units in Turkey using the APACHE II and SOFA systems (outcome assessment in Turkish intensive care units).

Authors:  Cetin Kaymak; Irfan Sencan; Seval Izdes; Aydin Sari; Hatice Yagmurdur; Derya Karadas; Derya Oztuna
Journal:  Arch Med Sci       Date:  2016-05-05       Impact factor: 3.318

9.  Urinary neutrophil gelatinase-associated lipocalin, kidney injury molecule-1, N-acetyl-β-D-glucosaminidase levels and mortality risk in septic patients with acute kidney injury.

Authors:  Heng Fan; Yu Zhao; Min Sun; Jian-Hua Zhu
Journal:  Arch Med Sci       Date:  2018-10-23       Impact factor: 3.318

10.  Scored minor criteria for severe community-acquired pneumonia predicted better.

Authors:  Qi Guo; Wei-Dong Song; Hai-Yan Li; Yi-Ping Zhou; Ming Li; Xiao-Ke Chen; Hui Liu; Hong-Lin Peng; Hai-Qiong Yu; Xia Chen; Nian Liu; Zhong-Dong Lü; Li-Hua Liang; Qing-Zhou Zhao; Mei Jiang
Journal:  Respir Res       Date:  2019-01-31
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.